TriSalus Life Sciences, Inc. (ticker: TLSI) is an NASDAQ-listed surgical & medical instruments & apparatus company. DredgeCap's structured extraction of TLSI's SEC filings surfaces 6 active risk signals, including 3 late-filing signals, 2 auditor-change signals, and 1 delisting/deregistration signal. TLSI reported $8.90M in revenue and $1.54M for the period ending 2026-03-31, with operating cash flow of -$6.48M. Cash and equivalents stood at $56.55M (up 335% year-over-year). Total assets of $70.98M exceed total liabilities of $58.17M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
TLSI SEC Filings
Full cached SEC EDGAR filing history for TLSI, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.